Abstract
Idarucizumab is a specific reversal agent for the novel oral anticoagulant (NOAC) dabigatran. Idarucizumab is indicated when rapid, complete and sustained reversal of dabigatran’s anticoagulant effect is needed, such as when the patient requires emergency surgery or an urgent procedure, or has life-threatening or uncontrolled bleeding.
| Original language | English |
|---|---|
| Pages (from-to) | 63-65 |
| Number of pages | 3 |
| Journal | Medicine Today |
| Volume | 17 |
| Issue number | 11 |
| Publication status | Published - 1 Nov 2016 |